Company Profile
Amneal Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- AMRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.09 USD (+0.95%)
Close
Last updated: July 27, 2026
4.04B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, AMRX closed up 0.95% at $18.09. No new same-company headline was identified in the current news window.
Company overview
Business overview
Amneal Pharmaceuticals is a global pharmaceutical company with generics, specialty products, and injectables. Its business is defined by scale, manufacturing, and portfolio breadth rather than early-stage biotech science.
Geographic Base and Sector Classification
Amneal is headquartered in the United States and listed on NASDAQ. It sits in diversified pharmaceuticals and generics.
Business Model Characteristics
The company generates value through product volume, manufacturing execution, and portfolio diversification. Investors watch margin trends, product launches, and debt or balance-sheet management.
Position Within the Biotechnology Landscape
Amneal is outside biotech and belongs in diversified pharma. It is driven by operating execution and portfolio management rather than clinical trial catalysts.
Future catalysts
Amneal’s catalysts are generics execution, specialty-pharma growth, and any margin or product-launch update that broadens the franchise. The company’s stock improves on steady operating execution.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
Source: Amneal Pharmaceuticals
- 02
Amneal to Report Second Quarter 2026 Results on July 30, 2026
Source: Amneal Pharmaceuticals
- 03
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEVA · Source: Teva Pharmaceutical Industries
- 04
Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector
Source: Amneal Pharmaceuticals
- 05
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
TEVA · Source: Teva Pharmaceutical Industries
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals (AMRX) most recently closed at 18.09 USD, a +0.95% move versus the previous session.
What is the market cap of Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals currently has a market capitalization of 4.04B USD on BioPharmSignal.
What does Amneal Pharmaceuticals do?
Amneal Pharmaceuticals is a global pharmaceutical company with generics, specialty products, and injectables. Its business is defined by scale, manufacturing, and portfolio breadth rather than early-stage biotech science.
On which exchange is AMRX stock listed?
Amneal Pharmaceuticals (AMRX) is associated with NASDAQ, United States, Biopharma.
What is Amneal?
Amneal’s catalysts are generics execution, specialty-pharma growth, and any margin or product-launch update that broadens the franchise.
Which conditions is Amneal Pharmaceuticals targeting with Amneal?
Amneal’s catalysts are generics execution, specialty-pharma growth, and any margin or product-launch update that broadens the franchise.
How does Amneal Pharmaceuticals describe recent progress with Amneal?
Amneal’s catalysts are generics execution, specialty-pharma growth, and any margin or product-launch update that broadens the franchise.
What is Pharmaceuticals?
Amneal Pharmaceuticals is a global pharmaceutical company with generics, specialty products, and injectables.